A Phase III Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab in Combination with Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subjects with Extensive Stage Small Cell Lung Cancer
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Merck
Start Date
March 24, 2017
End Date
June 30, 2022
Administered By
Duke Cancer Institute
Awarded By
Merck
Start Date
March 24, 2017
End Date
June 30, 2022